—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Nanobiotix S.A (NANO.PA) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for NANO.PA, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 57/100 · S&P 500 fund at 71, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-09
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +5.0% over 20 sessions. Factor regime → 2026-10-12
  • Sovereign pressure Index 0.04 · down 0.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-09
Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against NANO.PA on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Nanobiotix S.A

NANO.PA in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Nanobiotix is a clinical-stage biotechnology company that develops therapies for cancers and other conditions with high unmet need. Its main candidate, NBTXR3, is a nanoparticle-based suspension aimed at solid tumours such as soft tissue sarcoma, head and neck cancer and several others. It has a licensing partnership with Lian Oncology covering parts of Asia. The company is based in Paris.
Where it sits in the stack
Nanobiotix carries no Rubin seat and sits outside the AI build-out layers the diary tracks; it belongs to the healthcare sector, within biotechnology, a part of our universe we watch separately from the compute stack.
Who it is priced against
The diary holds no peer group for this name; it is not compared against any index sleeve or sector cohort in our coverage.
Why Closelooknet tracks it
Nanobiotix carries no index seat, no Closelooknet score and no quotes in the diary's editions; it remains outside the tracked coverage for now.
What the diary watches
The diary watches whether the Lian Oncology partnership advances toward commercial milestones, and whether the shares move far enough from the 200-day trend to warrant a fresh look.

Nanobiotix S.A (NANO.PA) trades on the PA exchange in France.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-13

Quick answers

What is Nanobiotix S.A (NANO.PA)?

Nanobiotix S.A trades as NANO.PA on the PA exchange (France) in the Closelooknet research universe, as of the registry build of 2026-10-13.

Is NANO.PA in a Closelooknet index?

Not currently — Nanobiotix S.A is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-13.

Where does NANO.PA trade against its moving averages?

Mixed moving-average stack: Trades -32.7% vs the 50-day and -27.4% vs the 200-day average, 56.1% below the 52-week high and +59.8% off the 52-week low. Computed from daily closes. As of 2026-10-12 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Nanobiotix S.A compare with its peers?

Against its peer group (Biotechnology), Nanobiotix S.A (NANO.PA) sits 56.1% below its 52-week high, 32.7% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 4.9% below, Argen-X (ARGX.BR) is 20.7% below, BeiGene, Ltd. (ONC) is 9.0% below. Put any of them next to NANO.PA in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Nanobiotix S.A do?

Nanobiotix is a clinical-stage biotechnology company that develops therapies for cancers and other conditions with high unmet need. Its main candidate, NBTXR3, is a nanoparticle-based suspension aimed at solid tumours such as soft tissue sarcoma, head and neck cancer and several others. It has a licensing partnership with Lian Oncology covering parts of Asia. The diary holds no peer group for this name; it is not compared against any index sleeve or sector cohort in our coverage.

Where does Nanobiotix S.A sit in the AI build-out?

Nanobiotix carries no Rubin seat and sits outside the AI build-out layers the diary tracks; it belongs to the healthcare sector, within biotechnology, a part of our universe we watch separately from the compute stack. Nanobiotix carries no index seat, no Closelooknet score and no quotes in the diary's editions; it remains outside the tracked coverage for now.

What does this page show?

A live price chart with SMA overlays and drawing tools for NANO.PA, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.